Clinical Trials
108 trialsClinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)
Universität Münster
INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
Pediatric Brain Tumor Consortium
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
Thomas Jefferson University
Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma
University of California, San Francisco
Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
National Cancer Institute (NCI)
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
St. Jude Children's Research Hospital
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
Istari Oncology, Inc.
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
National Cancer Institute (NCI)
HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors
University of Alabama at Birmingham
Stereotactic Radiosurgery in Treating Patients With Brain Tumors
National Institutes of Health Clinical Center (CC)
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
Children's Oncology Group
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
Columbia University
Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors
Mayo Clinic
Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma
Northwestern University
Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
G-FORCE-1
EpicentRx, Inc.
Safety Study of Afatinib for Brain Cancer
Saint John's Cancer Institute
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
City of Hope Medical Center
Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma
Jonsson Comprehensive Cancer Center
Vaccine Therapy in Treating Patients With Malignant Glioma
Jonsson Comprehensive Cancer Center
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
Jonsson Comprehensive Cancer Center
Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
Case Comprehensive Cancer Center
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
Mayo Clinic
AZD8055 for Adults With Recurrent Gliomas
National Institutes of Health Clinical Center (CC)
Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma
Memorial Sloan Kettering Cancer Center
Dexanabinol in Patients With Brain Cancer
University of California, San Diego
Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors
Medical College of Wisconsin
Carboplatin in Treating Patients With Recurrent High-Grade Gliomas
Ohio State University Comprehensive Cancer Center
Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gene Therapy in Treating Patients With Recurrent Malignant Gliomas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma
Tocagen Inc.
Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor
Tocagen Inc.
Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor
Tocagen Inc.
A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
City of Hope Medical Center
Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases
City of Hope Medical Center
A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas
City of Hope Medical Center
Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma
City of Hope Medical Center
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
Pediatric Brain Tumor Consortium
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
Roswell Park Cancer Institute
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Roswell Park Cancer Institute
alloCTL
Jonsson Comprehensive Cancer Center
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
National Cancer Institute (NCI)
Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
Duke University
Vaccine Therapy in Treating Patients With Malignant Glioma
Jonsson Comprehensive Cancer Center
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
National Cancer Institute (NCI)
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
City of Hope Medical Center